Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCureNXTC -3.77%28 EV-to-EBITDA is -0.57 as of Sep. 09, 2026. GuruFocus rates NXTC with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 400 Biotechnology companies, NextCure ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NextCure's enterprise value is $21.49 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-37.37 Mil. Therefore, NextCure's EV-to-EBITDA for today is -0.57.
The historical rank and industry rank for NextCure's EV-to-EBITDA or its related term are showing as below:
NXTC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.63 Med: 6.11 Max: 7.3
Current: -0.57
During the past 9 years, the highest EV-to-EBITDA of NextCure was 7.30. The lowest was -56.63. And the median was 6.11.
NXTC's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.615
vs NXTC: -0.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NextCure's share price for today is $8.295.
NextCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NextCure's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NextCure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NextCure's EV-to-EBITDA falls into.
NextCure's current Enterprise Value is $21.49 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NXTC) has a EV-to-EBITDA of -0.57 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NextCure. According to the industry distribution chart, NextCure ranks #999999 out of 400 companies in the Biotechnology industry.
Is NextCure's EV-to-EBITDA too high?
NextCure's current EV-to-EBITDA is -0.57. Based on the distribution chart, NextCure ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCure has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's EV-to-EBITDA compare to CVM and PLRZ?
According to the Biotechnology industry distribution chart, NextCure ranks #999999 out of 400 companies for EV-to-EBITDA. This places NextCure in the lower half of its industry. The industry median EV-to-EBITDA is 13.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.62, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NextCure. For the Biotechnology industry, the median EV-to-EBITDA is 13.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCure's current EV-to-EBITDA is -0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (NXTC) has a current EV-to-EBITDA of -0.57. The current EV-to-EBITDA is -0.57. NextCure's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NextCure (NXTC), the current EV-to-EBITDA is -0.57 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
28GF Score
Get the complete analysis for NXTC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXTC has been successfully added to your 
